Preventing cardiovascular and renal complications in patients with type 2 diabetes and microalbuminuria: the GP-Prompt study

Not Applicable

Completed

• Conditions: The intervention being tested is aimed at general practitioners and practice nurses. The intervention will support practices in managing patients with type 2 diabetes and microalbuminuria.; Not Applicable

• Registration Number: ISRCTN14918517
• Lead Sponsor: niversity of Leicester

Brief Summary

2018 protocol and baseline characteristics in https://www.ncbi.nlm.nih.gov/pubmed/29884609 2020 results in https://pubmed.ncbi.nlm.nih.gov/32430457/ (added 04/03/2021)

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2015-06-09
• Study Completion: 2017-06-30
• Last Update Posted: 15 March 2021

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 24

Inclusion Criteria

We aim to recruit 24 practices (12 intervention & 12 control) we will collect anonymised data from eligible patients registered at participating practices. Patients will be eligible if they have type 2 diabetes and microalbuminuria and are not excepted from quality outcomes framework (QOF) (whole domain diabetes) for any reason.

Exclusion Criteria

1. GP practices not located in Leicester City CCG, Leicester county east CCG or Leicester county west CCG will not be invited to take part in the study
2. GP practices with a list size of <6500 patients will not be invited to take part in the study

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Proportion (%) of patients meeting both of the following targets: BP <130/80 mmHg and total cholesterol <3.5mmol/l measured 24 months post-intervention.

Secondary Outcome Measures

Name	Time	Method
<br> 1. Incidence of CV events and all-cause mortality<br> 2. Glycaemic control assessed by HbA1c<br> 3. Progression in microalbuminuria assessed via albumin-creatinine ratio (ACR)<br> 4. Kidney function measured via estimated glomerular filtration rate (eGFR)<br> 5. Current type 2 diabetes mellitus medications (use of metformin, Sulphonylureas (SUs), insulin, thiazolidinediones (TZD), glucagon-like peptide-1 (GLP1), dipeptidyl peptidase-4 inhibitor (DPP4) or sodium-glucose linked transporters (SGLT2))<br> 6. Current BP or cholesterol medications (use of ACE inhibitors, ARBs, beta blockers, alpha blockers, aspirin, statins or exenatide)<br> 7. Current smoking status<br>